

September 6, 2007

Notice of the Result of Acquisition of the Company's Own Shares Through ToSTNeT-2

Japan, September 6, 2007 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it completed acquisition of its own shares in the market.

Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	6.5 million shares
3. Value of the transaction:	¥ 5,170
4. Period of acquisition:	September 6, 2007
5. Method of acquisition:	Purchased through ToSTNeT-2 (closing price transaction) of the Tokyo Stock Exchange

(Reference 1)

Resolution of the Board of Directors on August 28, 2007

- Reasons for acquisition of its own shares:	In order to improve capital efficiency and enhance return to shareholders
- Class of shares to be acquired:	Common stock of the Company
- Number of shares to be acquired:	8.3 million shares (maximum) (equivalent to 1.60% of a total of issued shares)
- Aggregate amount of acquisition cost:	¥ 45 billion (maximum)
- Period of acquisition:	From August 29, 2007 to September 20, 2007

(Reference 2)

Cumulative total of the its own shares after Resolution of the Board of Directors on August 28, 2007

1. Total number of shares purchased:	7,436,400 shares
2. Total value of purchase:	¥ 38,532,656,000

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com